Sustained administration of the antidepressant venlafaxine in rats: Pharmacokinetic and pharmacodynamic findings

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 363, Issue 4, 2001, Pages 448-455

  Wikell, C ^a   Hjorth, S ^a   Apelqvist, G ^a   Kullingsjo J ^a   Lundmark, J ^a   Bergqvist, P B F ^a   Bengtsson, F ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Antidepressant; Behavior; Biogenic monoamines; Microdialysis; Pharmacokinetics; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE; VENLAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION FUNCTION; LOCOMOTION; MALE; NEOCORTEX; NONHUMAN; OPEN FIELD BEHAVIOR; OSMOTIC MINIPUMP; PHARMACODYNAMICS; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BODY WEIGHT; CYCLOHEXANOLS; MALE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0035079695     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002100100405     Document Type: Article

References (46)

1. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study
2. Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-field
3. Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges
4. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters
5. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine. I. In vivo electrophysiological studies in the rat
6. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine. II. In vitro studies in the rat
7. Brain microdialysis
8. Neocortical dial-ysate monoamines of rats after acute, subacute, and chronic liver shunt
9. Cerebral flavin-containing monooxygenase-mediated metabolism of antidepressants in brain: Immunochemical properties and immunocytochemical localization
10. A racemic HPLC-method for routine TDM of the novel antidepressant venlafaxine and its main relevant metabolites in serum
11. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
12. Effect of antide-pressant drugs on the depletion of intraneuronal brain 5-hy-droxytryptamine stores caused by 4-methyl-a-ethyl-meta-tyramine
13. 1A receptor antagonism
14. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
15. Nucleus locus coeruleus: New evidence of anatomical and physiological specificity
16. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on the extracellular 5-HT: This effect persists after repeated citalopram treatment
17. Venlafaxine: Acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo
18. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: A microdialysis study
19. 1A autoreceptors in the action of selective serotonin reuptake inhibitors
20. Autoreceptors remain functional after prolonged treatment with a serotonin reuptake inhibitor
21. 1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol
22. Venlafaxine. A review of its pharmacology and therapeutic potential in depression
23. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man
24. Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals
25. Basic characteristics of noradrenaline release in the hippocampus of intact and 6-hydroxydopamine-lesioned rats as studied by in vivo microdialysis
26. cDNA cloning of a novel rat brain cytochrome P450 belonging to the CYP2D subfamily
27. Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18* catalyzing imipramine N-demethylation
28. A survey on quantitative microdialysis: Theoretical models and practical implications
29. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
30. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression
31. 1A agonists
32. Drug treatment of depression in the 1990s. An overview of achievements and future possibilities
33. Is there a role for a pure noradrenergic drug in the treatment of depression?
34. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivate
35. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the anti-depressant venlafaxine
36. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
37. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine
38. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine
39. Xenobiotic metabolism in brain
40. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain
41. Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation
42. 14C]2-deoxy-D-glucose autoradiography
43. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression
44. Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in brain: Putative implications for psychiatry and psychopharmacology
45. Characterization of cytochrome P-450 2D1 activity in rat brain: High-affinity kinetics for dextromethorphan
46. Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy